16/04/2026
The most meaningful validation comes from clinicians themselves.
In his LinkedIn post, Dr.M V Chandrakanth offers an unbiased comparison of prognostic approaches in HR+ HER2- early breast cancer: insights that help guide better decisions.
Oncotype DX vs CanAssist Breast Two different approaches to the same clinical question: ๐ Who really needs chemotherapy? ๐ฌ Oncotype DX โ genomic test โ Predicts chemo benefit + recurrence risk ๐งช CanAssist โ proteomic test โ Estimates recurrence risk using biology + clinical factors ...